Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkyePharma PLC

Division of Vectura Group PLC
www.skyepharma.com

Latest From SkyePharma PLC

Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review

Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.

Advisory Committees Aesthetics

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Deals M & A

Vectura CFO Sanguine Despite Flutiform Phase III COPD Trial Miss

Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.

Commercial Companies

INTERVIEW: Behind The Scenes Of Skyepharma's Financial Phoenix And Merger

Skyepharma's outgoing CEO Peter Grant, has been masterminding the company's return to profitability for a decade. He looks back on how he negotiated pharma's financial waters and how that led to the company's merger with UK competitor Vectura.

United Kingdom Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
      • Topical Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Vectura Group PLC
  • Senior Management
  • Peter Grant, CEO
    Andrew Derodra, CFO
    Kirsten Kaiser, EVP, Medicinal & Regulatory
    Geraldine Venthoye, EVP, Pharmaceutical Dev.
    Guy Vergnault, VP, Oral Drug Delivery Solutions
    Selene Daly, VP, Supply Chain
    Christian Pangratz, EVP, BD and Alliances
  • Contact Info
  • SkyePharma PLC
    Phone: (44) 207 881 0524
    46-48 Grosvenor Gardens
    London, SW1W 0EB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register